Advanced search×

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Karim Fizazi, Michael Carducci, Matthew Smith, Ronaldo Damião, Janet Brown, Lawrence Karsh, Piotr Milecki, Neal Shore, Michael Rader, Huei Wang, Qi Jiang, Sylvia Tadros, Roger Dansey, and Carsten Goessl

Lancet 377(9768):813-22 (2011) PMID 21353695 PMCID PMC3090685

Bone metastases are a major burden in men with advanced prostate cancer. We compared denosumab, a human monoclonal antibody against RANKL, with zoledronic acid for prevention of skeletal-related events in men with bone metastases from castration-resistant prostate cancer.

DOI: 10.1016/S0140-6736(10)62344-6
Version: za2963e q8za6 q8zb3 q8zcb q8zd8 q8zee q8zf6 q8zgb
View PDF

Similar articles you may find interesting…

  1. Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no eff...
    Toshio T Nishihara, Yasuo Y Miura, ... Kaoru K Tohyama

    Int J Hematol 78(3):233-40 (2003) PMID 14604282

    We investigated the effects of a Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate, on the proliferation, adhesive properties, and morphology of a Bcr-Abl-transferred cell line, TF-1 Bcr-Abl, in comparison with parental TF-1. First, the factor-independent growth of TF-1 Bcr-Abl was inhibited in t...
  2. Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intrav...
    K Fizazi, A Lipton, ... S Jun

    J Clin Oncol 27(10):1564-1571 (2009) PMID 19237632

    We evaluated the effect of denosumab, a fully human monoclonal antibody against RANKL, in patients with bone metastases and elevated uNTx levels despite ongoing intravenous (IV) bisphosphonate (BP) therapy. Patients and MethodsEligible patients had histologically confirmed malignancy, [≥] 1 bone...
  3. The Evolving Role of Bone-Conserving Therapy in Patients With Breast Cancer
    Adam M Brufsky

    Semin Oncol (2010) PMID 20682367

    Patients with breast cancer (BC) experience bone loss as a result of either cancer treatment or metastatic disease to the bone. In addition, baseline factors universally associated with bone loss have been identified, including history of fracture, menopausal status, oral corticoster...